(S)-5,5'-(4,4'-oxybis(4,1-phenylene))bis(2-((S)-pyrrolidin-2-yl)-1H-imidazole) | 1251195-93-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-5,5'-(4,4'-oxybis(4,1-phenylene))bis(2-((S)-pyrrolidin-2-yl)-1H-imidazole)
• 英文别名: 2-[(2S)-pyrrolidin-2-yl]-5-[4-[4-[2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl]phenoxy]phenyl]-1H-imidazole
• CAS: 1251195-93-3
• 化学式: C₂₆H₂₈N₆O
• 分子量: 440.548
• InChiKey: LAXMUWBBRNUIOD-VXKWHMMOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  90.6
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-5,5'-(4,4'-oxybis(4,1-phenylene))bis(2-((S)-pyrrolidin-2-yl)-1H-imidazole) 、 MOC-L-缬氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 14.0h， 生成 dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(oxybis(4,1-phenylene))bis(1H-imidazole5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate
  参考文献：
  名称：

  Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors

  摘要：

  NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several compounds that were synthesized and evaluated in a HCV genotype 1b replicon. The straight triphenyl linked compound 11a showed similar anti-HCV activity to the clinical compound BMS-790052 and a superior cytotoxicity profile in three different cell lines, with an EC50 value of 26 pM and a therapeutic index of over four million in an HCV replicon assay. This triphenyl analog warrants further preclinical evaluation as an anti-HCV agent. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.03.089
• 作为产物：
  描述：

  bis(p-bromoacetylphenyl) ether 在 盐酸 、 ammonium acetate 、 水 、 三乙胺 作用下， 以 甲醇 、 甲苯 、 乙腈 为溶剂， 反应 20.0h， 生成 (S)-5,5'-(4,4'-oxybis(4,1-phenylene))bis(2-((S)-pyrrolidin-2-yl)-1H-imidazole)
  参考文献：
  名称：

  Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors

  摘要：

  NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several compounds that were synthesized and evaluated in a HCV genotype 1b replicon. The straight triphenyl linked compound 11a showed similar anti-HCV activity to the clinical compound BMS-790052 and a superior cytotoxicity profile in three different cell lines, with an EC50 value of 26 pM and a therapeutic index of over four million in an HCV replicon assay. This triphenyl analog warrants further preclinical evaluation as an anti-HCV agent. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.03.089

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bender John A.

  公开号：US20110077280A1

  公开（公告）日：2011-03-31

  This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

  本公开涉及公式（I）定义的新化合物和含有这些新化合物的组合物。这些化合物是有用的抗病毒剂，特别是在抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白质的功能方面。因此，本公开还涉及使用这些新化合物或含有这些新化合物的组合物治疗HCV相关疾病或病情的方法。
• Diaryl Ethers
  申请人：Demin Samuel Dominique

  公开号：US20120034678A1

  公开（公告）日：2012-02-09

  Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.

  公式I的化合物：包括其所有可能的立体异构体，或其药学上可接受的盐和/或溶剂化物，以及制药配方和将公式I的化合物用作HCV抑制剂的用途。
• POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
  申请人：Coats Steven J.

  公开号：US20130210774A1

  公开（公告）日：2013-08-15

  The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

  本发明涉及化合物、组合物和方法，用于治疗或预防人类或其他动物宿主的丙型肝炎病毒（HCV）感染。这些化合物也可以作为药物组成物的药学上可接受的盐、前药和其他衍生物，用于治疗或预防HCV感染。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2414350B1

  公开（公告）日：2014-11-12
• US8796466B2
  申请人：——

  公开号：US8796466B2

  公开（公告）日：2014-08-05